Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Blockade of the PD-1-PD-L1 pathway by PD-1/PD-L1 mAbs (PD-1 mAb in the figure, for example) will upregulate and promote Th1 and Th17 cells and downregulate and inhibit Th2 cells and Tregs. Without ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four ...
The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...
Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...
Hosted on MSN18d
Uncovering the cause of regulatory T cell dysfunction in elderly-onset rheumatoid arthritisIn the arthritic environment, Treg cells exhibit altered metabolic activity, reduced suppressive function, and increased PD-1 expression. Moreover, increased type I interferon signaling has been ...
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...
LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback